S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:ATRA

Atara Biotherapeutics - ATRA Stock Forecast, Price & News

$2.80
-0.18 (-6.04%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.76
$3.04
50-Day Range
$2.83
$5.46
52-Week Range
$2.66
$10.01
Volume
936,528 shs
Average Volume
1.18 million shs
Market Capitalization
$268.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.86

Atara Biotherapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
587.5% Upside
$19.25 Price Target
Short Interest
Bearish
17.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.41mentions of Atara Biotherapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$129,165 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.17) to ($1.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

808th out of 1,009 stocks

Biological Products, Except Diagnostic Industry

139th out of 166 stocks


ATRA stock logo

About Atara Biotherapeutics (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
See More Headlines
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Company Calendar

Last Earnings
2/08/2023
Today
3/30/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATRA
Fax
N/A
Employees
578
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.25
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+430.6%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-228,300,000.00
Net Margins
-359.12%
Pretax Margin
-359.10%

Debt

Sales & Book Value

Annual Sales
$63.57 million
Book Value
$1.33 per share

Miscellaneous

Free Float
92,090,000
Market Cap
$268.60 million
Optionable
Optionable
Beta
0.99

Key Executives

  • Pascal TouchonPascal Touchon
    President, Chief Executive Officer & Director
  • Utpal KoppikarUtpal Koppikar
    Chief Financial Officer & Senior Vice President
  • Manher AJ Joshi
    Chief Medical Officer
  • Jakob DupontJakob Dupont
    Global Head-Research & Development
  • Anhco Nguyen
    Chief Scientific Officer













ATRA Stock - Frequently Asked Questions

Should I buy or sell Atara Biotherapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares.
View ATRA analyst ratings
or view top-rated stocks.

What is Atara Biotherapeutics' stock price forecast for 2023?

7 brokerages have issued 12 month price objectives for Atara Biotherapeutics' shares. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they predict the company's share price to reach $19.25 in the next twelve months. This suggests a possible upside of 587.5% from the stock's current price.
View analysts price targets for ATRA
or view top-rated stocks among Wall Street analysts.

How have ATRA shares performed in 2023?

Atara Biotherapeutics' stock was trading at $3.28 at the start of the year. Since then, ATRA stock has decreased by 14.6% and is now trading at $2.80.
View the best growth stocks for 2023 here
.

Are investors shorting Atara Biotherapeutics?

Atara Biotherapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 16,700,000 shares, an increase of 18.7% from the February 28th total of 14,070,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is currently 13.1 days.
View Atara Biotherapeutics' Short Interest
.

When is Atara Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ATRA earnings forecast
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings data on Wednesday, February, 8th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.11. The biotechnology company earned $0.22 million during the quarter, compared to analyst estimates of $60 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 140.05% and a negative net margin of 359.12%.

What ETFs hold Atara Biotherapeutics' stock?
What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (7.82%), Maverick Capital Ltd. (6.56%), Morgan Stanley (2.80%), Geode Capital Management LLC (1.92%), Citigroup Inc. (1.08%) and Dimensional Fund Advisors LP (0.94%). Insiders that own company stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends
.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $2.80.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $268.60 million and generates $63.57 million in revenue each year. The biotechnology company earns $-228,300,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

The company employs 578 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (805) 623-4211 or via email at ehyllengren@atarabio.com.

This page (NASDAQ:ATRA) was last updated on 3/30/2023 by MarketBeat.com Staff